...
首页> 外文期刊>Experimental Gerontology >Pharmacological prevention and treatment of vascular dementia: Approaches and perspectives
【24h】

Pharmacological prevention and treatment of vascular dementia: Approaches and perspectives

机译:血管性痴呆的药理防治:方法与观点

获取原文
获取原文并翻译 | 示例
           

摘要

Vascular dementia (VaD) is a common dementing illness. There are no pharmacological agents with a regulatory approval for its treatment or prevention. Review of published clinical trial reports indicates that early treatment of hypertension, a risk factor for stroke, reduces VaD risk and slows progression. However, unlike stroke, treatment of hyperlipidemia with statin class drugs or treatment of blood clotting abnormalities with acetylsalicylic acid do not appear to have an effect on VaD incidence or progression. Pharmacological agents for treatment of Alzheimer's dementia (AD) such as memantine or acetylcholinesterase inhibitors have small positive effects on cognition in VaD, which are likely due to their action on co-existing AD-related neuropathology. Drug development efforts using novel approaches such as patient stratification by their genotype are needed in order to address the increasing need for effective VaD therapeutics.
机译:血管性痴呆(VaD)是一种常见的痴呆症。没有药理学制剂具有治疗或预防方面的监管批准。对已发表的临床试验报告的回顾表明,高血压的早期治疗是中风的危险因素,可降低VaD风险并减缓进展。但是,与中风不同,用他汀类药物治疗高脂血症或用乙酰水杨酸治疗凝血异常似乎不会对VaD发生或进展产生影响。美金刚或乙酰胆碱酯酶抑制剂等用于治疗阿尔茨海默氏痴呆(AD)的药物对VaD认知的积极作用较小,这很可能是由于它们对与AD相关的神经病理学共存的作用。为了解决对有效VaD疗法日益增长的需求,需要使用新颖的方法,例如按患者的基因型对患者进行分层的药物开发工作。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号